[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A, Carpenter TO: Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res; 2006 Oct;21(10):1666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
  • Histologic features typical of a benign adenoma were evident after surgical extirpation of the gland.
  • He was found to have a PT adenoma with aggressive features.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Germ-Line Mutation. Hyperparathyroidism, Primary / genetics. Parathyroid Neoplasms / diagnosis. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995822.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K24-HD01288; United States / NCRR NIH HHS / RR / M01-RR000125
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


2. Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, Duh QY, Clark OH: Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer; 2007 Jul 15;110(2):255-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?
  • BACKGROUND: Parathyroid carcinoma, atypical parathyroid adenoma, and parathyromatosis can be differentiated relatively easily from typical parathyroid adenomas, but distinguishing them from each other is more difficult.
  • METHODS: A retrospective study of 28 consecutive patients with parathyroid carcinoma, 7 patients with atypical parathyroid adenoma, and 13 patients with parathyromatosis who were treated at the University of California at San Francisco Medical Center between 1966 and 2005 was performed.
  • RESULTS: Parathyroid carcinoma (19 of 28 patients) and atypical adenoma (4 of 7 patients) were significantly more common in men, whereas parathyromatosis was more common in women (10 of 13 patients) (P = .02).
  • Prior to the first parathyroid surgery, patients with parathyroid carcinoma were found to have higher blood calcium levels (>/=14 mg/dL in 16 of 26 patients [62%]), whereas only 1 of 6 patients with atypical adenoma (17%) and no patients with parathyromatosis were found to have profound hypercalcemia (P < .01).
  • Intraoperatively, patients with parathyroid carcinoma and atypical adenoma presented with single lesions, whereas patients with parathyromatosis had multiple small lesions.
  • CONCLUSIONS: Patients with parathyroid carcinoma often differ from those with atypical parathyroid adenoma or parathyromatosis at the time of presentation because patients with parathyroid carcinoma have more profound hypercalcemia as well as invasive tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Hyperparathyroidism / pathology. Parathyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559137.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S, Bilezikian JP, Pinchera A, Marcocci C: Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest; 2008 Oct;31(10):900-4
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HRPT2 and parafibromin studies improved the diagnostic accuracy in two patients with primary hyperparathyroidism (PHPT) referred to us after surgery, in whom the clinical data were at variance with the pathological diagnosis of adenoma and carcinoma, respectively.
  • Patient #2, with severe PHPT, had had the removal of a 3.5-cm tumor described histologically as adenoma.
  • Re-review of the initial histology showed a trabecular pattern, fibrous bands, and atypical mitoses, suggesting an atypical adenoma.
  • Because of the suspicion that case #1 could be an atypical adenoma and case #2 a carcinoma further molecular studies were performed.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Carcinoma / genetics. Carcinoma / pathology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • Genetic Alliance. consumer health - Hyperparathyroidism 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):757-61 [7906387.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1140-9 [16931959.001]
  • [Cites] J Bone Miner Res. 2006 Oct;21(10):1666-71 [16995822.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):2827-32 [16720667.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6629-37 [15475453.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):501-12 [17639063.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5583-91 [15531515.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] J Endocrinol Invest. 1998 Mar;21(3):136-41 [9591207.001]
  • [Cites] Eur J Endocrinol. 2007 May;156(5):547-54 [17468190.001]
  • [Cites] World J Surg. 1999 Jan;23(1):68-74 [9841766.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):99-106 [14678295.001]
  • (PMID = 19092296.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK032333
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


Advertisement
4. Montenegro FL, Tavares MR, Durazzo MD, Cernea CR, Cordeiro AC, Ferraz AR: Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J; 2006 Jan 5;124(1):42-4
Genetic Alliance. consumer health - Parathyroid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One atypical adenoma was observed.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Hyperparathyroidism / surgery. Parathyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612462.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Smolka W, Eggensperger N, Stauffer-Brauch EJ, von Bredow F, Lizuka T: Pleomorphic adenoma in an atypical location near the temporomandibular joint: a case report. Quintessence Int; 2007 May;38(5):417-21
MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma in an atypical location near the temporomandibular joint: a case report.
  • In this report, a pleomorphic adenoma in an atypical location--the region of the temporomandibular joint (TMJ)--is presented.
  • This report shows that pleomorphic adenoma can be a possible diagnosis for lesions at the joint capsule.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Temporomandibular Joint / pathology. Temporomandibular Joint Disorders / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568841.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH: Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer; 2009 Jan 15;115(2):334-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It is frequently difficult to establish histologically whether a parathyroid tumor is a parathyroid carcinoma, parathyromatosis, or an atypical adenoma.
  • METHODS: Samples of parathyroid carcinoma, atypical adenoma, parathyromatosis, parathyroid adenoma, and hyperplasia were obtained for tissue microarray studies.
  • RESULTS: Complete loss of parafibromin expression was seen in 5 of 16 (31.3%) parathyroid carcinomas; all parathyromatosis, atypical adenomas, adenomas, and hyperplasia stained positive for parafibromin.
  • Loss of Rb expression was seen in 5 (33.3%) of 15 parathyroid carcinomas and 1 (7.1%) of 14 parathyroid hyperplasias; all parathyromatosis, atypical adenomas, and adenomas stained positive.
  • Galectin-3 stained strongly positive in 14 (93.3%) of 15 parathyroid carcinomas, and positive in 3 (18.7%) of 16 cases of parathyromatosis, 2 (100%) of 2 atypical adenomas, 1 (5.6%) of 18 adenomas, and 2 (14.3%) of 14 hyperplasias.
  • The Ki-67 proliferative index was high in 9 (60%) of 15 parathyroid carcinomas, 1 (6.7%) of 15 cases of parathyromatosis, 1 (5.6%) of 18 adenomas, and no atypical adenomas or hyperplasia.
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma / diagnosis. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Parathyroid Diseases / diagnosis. Phenotype. Tissue Array Analysis. Tumor Suppressor Proteins / analysis

  • Genetics Home Reference. consumer health - CDC73 gene.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19107770.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Galectin 3; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


7. Ulu EM, Uyuşur A, Ekici Y, Hunca C, Coşkun M: Multidetector CT findings of spontaneous rupture of hepatic adenoma in a patient with hepatic adenomatosis. Diagn Interv Radiol; 2009 Jun;15(2):135-8
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector CT findings of spontaneous rupture of hepatic adenoma in a patient with hepatic adenomatosis.
  • We report the case of a 32-year-old woman who presented with a large intraparenchymal and subcapsular hematoma in the liver, and an underlying large adenoma with atypical radiologic characteristics detected with multidetector CT imaging.
  • On follow-up CT examination, a large adenoma was clearly visualized at the site of the previous hematoma.
  • [MeSH-major] Adenoma / diagnosis. Hematoma / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517384.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


8. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol; 2007 Feb;156(2):203-16
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenomas (100%) were classified into densely granulated GH cell adenomas (9.2%), sparsely granulated GH cell adenomas (6.3%), sparsely granulated prolactin (PRL) cell adenomas (8.9%), densely granulated PRL cell adenomas (0.3%), mixed GH/PRL cell adenomas (5.2%), mammosomatotropic adenomas (1.1%), acidophilic stem cell adenomas (0.2%), densely granulated ACTH cell adenomas (7.2%), sparsely granulated ACTH cell adenomas (7.9%), Crooke cell adenomas (0.03%), TSH cell adenomas (1.5%), FSH/LH cell adenomas (24.8%), null cell adenomas (19.3%), null cell adenoma, oncocytic variant (5.8%), and plurihormonal adenomas (1.3%).
  • Following the WHO classification of 2004, the new entity 'atypical adenoma' was found in 12 cases in 2005.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287410.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 98
  •  go-up   go-down


9. Di Carlo I, Pulvirenti E, Toro A, Priolo GD: Adenoma or atypical hepatic focal nodular hyperplasia: role of preoperative imaging and laparoscopic treatment. Surg Laparosc Endosc Percutan Tech; 2010 Jun;20(3):e105-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoma or atypical hepatic focal nodular hyperplasia: role of preoperative imaging and laparoscopic treatment.
  • Differentiation of focal nodular hyperplasia (FNH) and other hypervascular liver lesions, such as hepatocellular adenoma (HCA), is important because of the drastically different therapeutic approach.
  • However, FNH can be well distinguished only if it shows a typical aspect; alternatively, in the case of atypical FNH, imaging findings are not specific enough to provide a secure diagnosis and histologic verification of the lesion is required.
  • The pathologic examination diagnosed an atypical FNH nodule.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Focal Nodular Hyperplasia / diagnosis. Laparoscopy. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551788.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Okamoto T, Iihara M, Obara T, Tsukada T: Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg; 2009 Nov;33(11):2343-54
Genetic Alliance. consumer health - Parathyroid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between unequivocal and equivocal carcinoma (or atypical adenoma) was not always made for the study populations.
  • None of the patients with "atypical adenoma" developed recurrence, whereas 25% of those with "equivocal carcinoma" did.
  • [MeSH-minor] Adenoma. Humans. Mutation. Odds Ratio. Prognosis. Risk Factors. Sensitivity and Specificity. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1984 Dec;37(12):1370-8 [6511982.001]
  • [Cites] Endocr J. 2001 Apr;48(2):213-7 [11456270.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):724-31 [1413841.001]
  • [Cites] Medicine (Baltimore). 1992 Jul;71(4):197-205 [1518393.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1555-62 [2208008.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3413-20 [15240624.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):820-9 [8338192.001]
  • [Cites] Lancet. 1984 Nov 3;2(8410):1043 [6149425.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):343-57 [3551149.001]
  • [Cites] Surgery. 1983 Dec;94(6):906-15 [6648803.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):526-32 [15889214.001]
  • [Cites] Postgrad Med J. 1994 Mar;70(821):231-2 [8183761.001]
  • [Cites] World J Surg. 1984 Jun;8(3):392-400 [6464494.001]
  • [Cites] Ann Surg. 1966 Nov;164(5):917-20 [5923121.001]
  • [Cites] Am J Surg. 1985 Apr;149(4):522-7 [3985291.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1973 Aug 9;360(2):107-22 [4200384.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Ann R Coll Surg Engl. 1985 Jul;67(4):222-4 [4037630.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(3):363-70 [7445424.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):878-85 [11485522.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):563-9 [15369455.001]
  • [Cites] Eur J Endocrinol. 2000 Mar;142(3):300-6 [10700726.001]
  • [Cites] Surgery. 1984 Dec;96(6):1132-7 [6505966.001]
  • [Cites] Cancer. 1972 Apr;29(4):1016-20 [4552809.001]
  • [Cites] Clin Oncol. 1984 Mar;10(1):11-9 [6231153.001]
  • [Cites] Ann Intern Med. 1987 Nov;107(5):683-6 [2821862.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 May;2(5):291-6; quiz 297 [16932300.001]
  • [Cites] Ann Surg. 1969 Apr;169(4):631-40 [4886854.001]
  • [Cites] Intern Med. 1994 Feb;33(2):123-6 [7912571.001]
  • [Cites] Cancer. 1973 Mar;31(3):600-5 [4693587.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):370-3 [9950443.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Am J Med. 1982 Jun;72(6):939-44 [6211978.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):383-9 [11417985.001]
  • [Cites] J Clin Pathol. 1977 Oct;30(10):966-75 [412876.001]
  • [Cites] BMJ. 2000 May 6;320(7244):1283 [10797065.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):321-4 [11393187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):569-72 [9635703.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5015-7 [15956079.001]
  • [Cites] Surg Oncol. 1999 Nov;8(3):155-65 [11113666.001]
  • [Cites] Surgery. 2007 Dec;142(6):936-43; discussion 943.e1 [18063079.001]
  • [Cites] Am J Hum Genet. 1995 Apr;56(4):944-50 [7717405.001]
  • [Cites] Surgery. 1993 Dec;114(6):1040-8; discussion 1048-9 [8256207.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Am Surg. 2006 May;72(5):419-26 [16719197.001]
  • [Cites] Am Surg. 2003 Sep;69(9):779-83 [14509326.001]
  • [Cites] N Engl J Med. 1970 Sep 17;283(12):634-6 [5450637.001]
  • [Cites] Am J Surg. 1984 Feb;147(2):292-8 [6696206.001]
  • [Cites] Am J Clin Pathol. 1981 Mar;75(3):345-7 [7211756.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jun;38(6):659-61 [8334754.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2378-84 [14635072.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1345-53 [16237743.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5583-91 [15531515.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8 [17666472.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):54-64 [12605367.001]
  • [Cites] Ann Surg. 1981 Apr;193(4):425-35 [7212805.001]
  • [Cites] Medicina (B Aires). 1991;51(2):106-10 [1820495.001]
  • [Cites] Cleve Clin J Med. 1993 Jul-Aug;60(4):331-5 [8339458.001]
  • [Cites] Arch Intern Med. 1984 Feb;144(2):399-400 [6696578.001]
  • [Cites] BMJ. 2005 May 21;330(7501):1179 [15894554.001]
  • [Cites] BMJ. 2004 May 1;328(7447):1040 [15073027.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):908-14 [16112008.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1083-8 [9543122.001]
  • [Cites] Medicine (Baltimore). 2002 Jan;81(1):1-26 [11807402.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] Semin Surg Oncol. 1997 Mar-Apr;13(2):134-41 [9088069.001]
  • [Cites] Surgery. 1987 Jun;101(6):649-60 [3589961.001]
  • [Cites] Head Neck. 2004 Aug;26(8):716-26 [15287039.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Sep;67(3):370-6 [17555500.001]
  • (PMID = 19350316.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


11. Lautz TB, Finegold MJ, Chin AC, Superina RA: Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J Pediatr Surg; 2008 Apr;43(4):751-4
Hazardous Substances Data Bank. CARBAMAZEPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy.
  • An association between oxcarbazepine therapy and hepatic adenoma (HA) has been documented in animal models but not observed in humans.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Anticonvulsants / adverse effects. Carbamazepine / analogs & derivatives. Liver Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405728.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


12. Bondarenko VO, Depiui TI, Magomedov RB, Shapiro NA: [The role of urgent intraoperative morphological investigation in differential diagnostics of pretumor lesions and tumors of the thyroid]. Vestn Khir Im I I Grek; 2010;169(2):42-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was shown that the data of intraoperative cytological and histological diagnostics were comparable, the cytological diagnosis of atypical adenoma being an indication to urgent histological investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552789.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


13. Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, Minisola S, Mascia ML, D'Agruma L, Cole DE: Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab; 2006 Aug;91(8):2827-32
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS, METHODS, AND RESULTS: In a 40-yr-old male previously treated for parathyroid atypical adenoma, we screened the 17 translated HRPT2 exons and their exon-intron boundaries and found a germline frameshift mutation in exon 7 (685delAGAG) predicting a premature stop codon at nucleotides 767-769.
  • Biochemical and ultrasonographic evaluation uncovered a 27-yr-old hypercalcemic carrier niece with an atypical parathyroid adenoma, and a 43-yr-old normocalcemic carrier sister was found by ultrasonography to have an extrathyroidal nodule, which proved to be parathyroid carcinoma.
  • The index case, 12 yr after surgery, was normocalcemic, but ultrasonography revealed an extrathyroidal nodule in the contralateral hemithyroid tissue that proved to be atypical adenoma.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Adenoma / surgery. Adult. Aged. Calcium / blood. Chromatography, High Pressure Liquid. Female. Heterozygote. Humans. Male. Middle Aged. Pedigree. Polymerase Chain Reaction. Sensitivity and Specificity

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2006 Aug;91(8):2861-3 [16894022.001]
  • (PMID = 16720667.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins; SY7Q814VUP / Calcium
  •  go-up   go-down


14. Dinleyici EC, Dogruel N, Acikalin MF, Tokar B, Oztelcan B, Ilhan H: An additional child case of an aldosterone-producing adenoma with an atypical presentation of peripheral paralysis due to hypokalemia. J Endocrinol Invest; 2007 Nov;30(10):870-2
MedlinePlus Health Information. consumer health - Paralysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An additional child case of an aldosterone-producing adenoma with an atypical presentation of peripheral paralysis due to hypokalemia.
  • Aldosterone-producing adenoma, which is characterized by hypertension, hypokalemia, and elevated aldosterone levels with suppressed plasma renin activity, is a rare condition during childhood and is also potentially curable.
  • To the best of our knowledge, nearly 25 cases of childhood aldosterone-secreting adenoma have been reported in the literature to date.
  • Here we describe a 13-yr-old girl with primary hyperaldosteronism secondary to aldosterone-secreting adenoma.
  • Laparoscopic adrenalectomy was performed and histopathological examinations showed benign adrenal adenoma.
  • [MeSH-major] Adenoma / complications. Adrenal Gland Neoplasms / complications. Hyperaldosteronism / etiology. Hypokalemia / etiology. Paralysis / etiology

  • Genetic Alliance. consumer health - Hypokalemia.
  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pediatr. 2001 Feb;160(2):114-6 [11271382.001]
  • [Cites] J Pediatr Surg. 1996 Mar;31(3):430-2 [8708918.001]
  • [Cites] Eur J Pediatr. 1994 Oct;153(10):715-7 [7813526.001]
  • [Cites] J Pediatr Surg. 1994 Oct;29(10):1388-91 [7807333.001]
  • [Cites] Clin Pediatr (Phila). 1988 Jul;27(7):344-7 [3292104.001]
  • [Cites] Am J Dis Child. 1984 Jul;138(7):673-6 [6375348.001]
  • [Cites] Rheumatol Int. 2005 Mar;25(2):133-4 [15034751.001]
  • [Cites] J Pediatr Surg. 1999 Dec;34(12):1878-80 [10626881.001]
  • (PMID = 18075291.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  •  go-up   go-down


15. Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C: Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol; 2010 Sep;21(3):166-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
  • A dilemma arises when tumours present with atypical histopathological features but lack direct evidence of malignancy.
  • We report results from APC and parafibromin expression analyses by immunohistochemistry and Western blot in five cases of atypical adenoma, a single case of carcinoma and 54 adenomas without atypical features.
  • Complete loss of APC immunoreactivity and reduced expression of parafibromin was evident in two of the atypical adenomas and in the parathyroid carcinoma.
  • We conclude that loss of APC is a frequent molecular event in atypical adenomas and carcinomas, but not in adenomas.
  • Furthermore, the molecular resemblance of atypical adenomas with carcinoma concerning parafibromin and APC expression indicates that atypical adenomas should be subjects to watchful follow-up.
  • [MeSH-major] Adenoma / metabolism. Adenomatous Polyposis Coli Protein / biosynthesis. Biomarkers, Tumor / analysis. Parathyroid Neoplasms / metabolism. Tumor Suppressor Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452-6 [1316610.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7405-11 [15492263.001]
  • [Cites] Am J Clin Pathol. 1991 Nov;96(5):669-71 [1719801.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Endocr Pathol. 2008 Winter;19(4):221-5 [19058032.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):485-93 [11157996.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):16-22 [16357559.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1140-9 [16931959.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):434-41 [19017757.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):594-8; discussion 599 [7725750.001]
  • [Cites] Surgery. 2008 May;143(5):630-40 [18436011.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5015-7 [15956079.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6629-37 [15475453.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):338-44 [17047023.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Br J Surg. 2007 May;94(5):566-70 [17380564.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):501-12 [17639063.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5583-91 [15531515.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):383-8 [8575862.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):481-92 [19148484.001]
  • (PMID = 20473645.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Schittenhelm J, Psaras T, Honegger J, Trautmann K, Meyermann R, Beschorner R: No evidence for WT1 involvement in a beta-catenin-independent activation of the Wnt signaling pathway in pituitary adenomas. Endocr Pathol; 2009;20(3):158-62
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated WT1 expression in 90 paraffin-embedded pituitary adenomas, including eight atypical adenomas, and in 28 nontumorous pituitary glands by immunohistochemistry.
  • Only two GHomas (including one atypical adenoma) and one gonadotropin-producing adenoma expressed WT1 in the cytoplasm of single tumor cells without nuclear staining.
  • [MeSH-major] Adenoma / metabolism. Pituitary Neoplasms / metabolism. Signal Transduction / physiology. WT1 Proteins / biosynthesis. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 2007 Jan 01;12:2279-90 [17127464.001]
  • [Cites] Annu Rev Genet. 1994;28:523-58 [7893139.001]
  • [Cites] J Pathol. 1997 Jan;181(1):67-74 [9072005.001]
  • [Cites] Pathologe. 1985 Nov;6(6):308-12 [4088978.001]
  • [Cites] Int J Gynecol Pathol. 2008 Oct;27(4):507-14 [18753972.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Histopathology. 2005 Jul;47(1):67-73 [15982325.001]
  • [Cites] Endocr Relat Cancer. 2000 Mar;7(1):3-15 [10808192.001]
  • [Cites] Mol Cell Biol. 1991 Mar;11(3):1707-12 [1671709.001]
  • [Cites] Gene Expr. 2006;13(1):1-14 [16572586.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):538-42 [19051831.001]
  • [Cites] Pathologe. 1995 Sep;16(5):354-8 [7479609.001]
  • [Cites] Hum Mol Genet. 2008 May 1;17(9):1278-91 [18250097.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):415-22 [7845666.001]
  • [Cites] Cancer Sci. 2004 Oct;95(10):822-7 [15504250.001]
  • [Cites] Eur J Endocrinol. 2008 Mar;158(3):287-94 [18299460.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):921-5 [11221883.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):226-32 [10782896.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Endocr Pathol. 2008 Winter;19(4):261-73 [19034702.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):271-6 [12824921.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):78-82 [7927908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5100-4 [8389468.001]
  • [Cites] Neuropathol Appl Neurobiol. 2009 Feb;35(1):69-81 [18466223.001]
  • [Cites] Oncogene. 2002 May 2;21(19):2948-60 [12082525.001]
  • [Cites] J Biol Chem. 2007 Oct 19;282(42):30938-48 [17720811.001]
  • [Cites] Arch Dermatol. 2005 Oct;141(10):1297-300 [16230568.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):804-14 [16547468.001]
  • (PMID = 19437143.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor Pit-1; 0 / WT1 Proteins; 0 / beta Catenin
  •  go-up   go-down


17. Marucci G, Faustini-Fustini M, Righi A, Pasquini E, Frank G, Agati R, Foschini MP: Thyrotropin-secreting pituitary tumours: significance of "atypical adenomas" in a series of 10 patients and association with Hashimoto thyroiditis as a cause of delay in diagnosis. J Clin Pathol; 2009 May;62(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyrotropin-secreting pituitary tumours: significance of "atypical adenomas" in a series of 10 patients and association with Hashimoto thyroiditis as a cause of delay in diagnosis.
  • BACKGROUND: Thyrotropin-secreting adenomas (TSH-As) are rare and, according to the World Health Organization criteria (WHO 2004), a significant proportion of them present features of atypical adenomas at the time of diagnosis.
  • AIMS: To determine the frequency of "atypical adenomas" and the significance of this definition as regards follow-up.
  • Three cases met the criteria for classification as atypical.
  • In none of the cases, including the three "atypical adenomas", were clinical or radiological signs of recurrence observed.
  • CONCLUSIONS: The three cases with features of atypical adenoma did not recur or metastasise, suggesting that, at least in the present series, a strict relationship between the morphological criteria for diagnosing atypical adenomas and biological behaviour may be sometimes lacking.
  • [MeSH-major] Adenoma / diagnosis. Hashimoto Disease / complications. Pituitary Neoplasms / diagnosis. Thyrotropin / secretion

  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098060.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


18. Liu FH, Hsueh C, Chao TC, Lin JD: Neck nodule and thyroid cancer in young without radiation exposure history. Pediatr Surg Int; 2009 Sep;25(9):785-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 234 cases, 187 (79.9%) were surgically confirmed to be benign lesions, including four cases that were diagnosed as atypical adenoma.
  • [MeSH-minor] Adenoma / pathology. Adolescent. Biopsy, Fine-Needle. Carcinoma / pathology. Child. Child, Preschool. Cysts / pathology. Female. Hemangioma, Capillary / pathology. Humans. Infant. Lymphoma / pathology. Male. Neck / diagnostic imaging. Neurofibroma / pathology. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Thyroiditis / pathology. Ultrasonography. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Nov 15;58(10):2329-32 [3756778.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):262-9 [16249278.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1331-5 [15956492.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):568-73 [11340614.001]
  • [Cites] Ear Nose Throat J. 2006 Jul;85(7):452-3 [16909820.001]
  • [Cites] Diagn Cytopathol. 1999 Mar;20(3):164-6 [10086242.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Dec;65(6):1088-94 [3680475.001]
  • [Cites] Surgery. 2008 Dec;144(6):963-8; discussion 968-9 [19041004.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Aug;118(4):566-72 [3400406.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Nov;78(1):102-4 [7987796.001]
  • [Cites] Thyroid. 2009 Jan;19(1):27-31 [19021460.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6 [11443191.001]
  • [Cites] Laryngoscope. 2006 Nov;116(11):2086-8 [17075428.001]
  • [Cites] J Clin Ultrasound. 1997 Mar-Apr;25(3):111-8 [9058259.001]
  • [Cites] Eur J Cancer. 2009 Jun;45(9):1624-9 [19179067.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2186-90 [2004338.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):4-6 [19092372.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Oct;135(4):581-4 [17011421.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):666-9 [12874762.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Dec;93(12 ):4840-3 [18812481.001]
  • [Cites] J Pediatr Surg. 2003 Oct;38(10):1557-9 [14577090.001]
  • [Cites] JAMA. 1962 Sep 22;181:1034-8 [14479999.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):189-92 [15754376.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):W293-8 [19020218.001]
  • (PMID = 19629501.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Ogawa Y, Watanabe M, Tominaga T: Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report. Endocr Pathol; 2010 Jun;21(2):130-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.
  • Atypical adenoma has an aggressive biological character, invades the surrounding structures, and grows rapidly.
  • Null cell adenoma generally grows slowly, but hormone secretion is little understood.
  • Atypical null cell adenoma is rare, and hormone production is unknown.
  • Histological examination showed atypical null cell adenoma with significant nuclear atypism and extensive necrosis.
  • Atypical null cell adenoma has an aggressive biological character, and immediate adjuvant treatment is essential.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology. Somatostatin / biosynthesis

  • Genetic Alliance. consumer health - Hypopituitarism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Endocr Pathol. 2010 Dec;21(4):277
  • [Cites] Histopathology. 2002 Mar;40(3):291-3 [11895496.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):179-88 [17047381.001]
  • [Cites] J Clin Pathol. 2002 Feb;55(2):148-51 [11865014.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2125 [19440039.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):91-5 [17987261.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):809-14 [7889618.001]
  • [Cites] Acta Neuropathol. 2001 Aug;102(2):117-20 [11563625.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):231-8 [14586068.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3089-99 [15741248.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Eur J Endocrinol. 2006 Oct;155(4):523-34 [16990651.001]
  • [Cites] Endocrine. 2005 Oct;28(1):27-35 [16311407.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):575-8 [10757406.001]
  • [Cites] Histopathology. 2002 Dec;41(6):559-61 [12460210.001]
  • [Cites] C R Acad Sci III. 1988;306(4):161-6 [2896067.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Mar;68(3):572-7 [2493037.001]
  • [Cites] J Endocrinol Invest. 2009 Jul;32(7):581-4 [19509474.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):93-6 [16648809.001]
  • [Cites] Neurosurgery. 2005 May;56(5):1066-74; discussion 1066-74 [15854256.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]
  • [Cites] Histopathology. 2009 Jan;54(2):254-7 [19207951.001]
  • [Cites] Pathol Biol (Paris). 1989 Sep;37(7):840-5 [2576565.001]
  • (PMID = 20174891.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


20. Raica M, Cimpean AM, Ribatti D: Angiogenesis in pre-malignant conditions. Eur J Cancer; 2009 Jul;45(11):1924-34
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additional evidences came from pre-malignant lesions of glandular epithelia, in which the angiogenic switch was demonstrated by the immunohistochemical expression of VEGF in gastric metaplasia and dysplasia, in atypical adenoma of the colon, atypical hyperplasia and carcinoma in situ of the breast and others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406633.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 93
  •  go-up   go-down


21. Ogawa Y, Tominaga T: A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment. J Neurooncol; 2008 Mar;87(1):91-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.
  • OBJECTIVE AND IMPORTANCE: Thyrotroph cell adenoma accounts for only 1% of all pituitary adenomas.
  • Atypical adenoma has an aggressive biological character, invades the surrounding structures, and grows rapidly.
  • Atypical thyrotroph cell adenoma is extremely rare.
  • Histological examination showed atypical thyrotroph cell adenoma.
  • CONCLUSION: Atypical thyrotroph cell adenoma has an aggressive biological character and grows rapidly.
  • [MeSH-major] Adenoma / therapy. Neoplasm Recurrence, Local / therapy. Pituitary Neoplasms / therapy. Thyrotrophs / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Sep;54(2):179-86 [11761434.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):179-88 [17047381.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Feb;40(2):275-8 [7511073.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):194-200 [10930003.001]
  • [Cites] Pituitary. 1999 May;1(3-4):221-6 [11081201.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Feb;76(2):529-33 [8432799.001]
  • [Cites] Endocrine. 2005 Oct;28(1):27-35 [16311407.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] No Shinkei Geka. 2007 Jul;35(7):679-84 [17633511.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] Pituitary. 2002;5(2):83-8 [12675505.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):708-11 [14764785.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):519-27 [10366408.001]
  • (PMID = 17987261.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; RWM8CCW8GP / Octreotide
  •  go-up   go-down


22. Ogawa Y, Ikeda H, Tominaga T: Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%. J Endocrinol Invest; 2009 Jul;32(7):581-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pituitary adenoma is generally indolent, but an aggressive subtype including atypical adenoma has uncertain prognosis, and an unclear relationship between prognosis and morphology.
  • SUBJECTS AND METHODS: Patients with surgically treated pituitary adenomas with Ki-67 labeling index of more than 3% were retrospectively identified as 13 males and 20 females aged from 15 to 73 yr (mean 47.2 yr) among 527 patients with pituitary adenoma treated at the Department of Neurosurgery, Tohoku University and Department of Neurosurgery, Kohnan Hospital between January 2001 and December 2007.
  • CONCLUSIONS: Gross total removal is the most important prognostic factor in patients with adenoma with Ki-67 labeling index of more than 3%.
  • In contrast, giant adenoma carries higher risk of recurrence and/or re-growth.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):179-88 [17047381.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):91-5 [17987261.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):809-14 [7889618.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):884-91 [16776331.001]
  • [Cites] Eur J Endocrinol. 2003 Aug;149(2):123-7 [12887289.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3089-99 [15741248.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Eur J Endocrinol. 2006 Oct;155(4):523-34 [16990651.001]
  • [Cites] Endocrine. 2005 Oct;28(1):27-35 [16311407.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):93-6 [16648809.001]
  • [Cites] Neurosurgery. 2005 May;56(5):1066-74; discussion 1066-74 [15854256.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]
  • (PMID = 19509474.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Sahli R, Christ ER, Seiler R, Kappeler A, Vajtai I: Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review. Pathol Res Pract; 2006;202(6):457-64
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With MIB-1 labeling indices of 1-3%, none of the tumors qualified as atypical adenoma.
  • Subtle morphologic evidence of corticotroph suppression in residual pituitary adjacent to tumor lends further support to literature data indicating minimal or intermittent functional activity in this tumor type.
  • [MeSH-major] Adenoma / pathology. Adrenocorticotropic Hormone / metabolism. Pituitary Gland, Anterior / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497445.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


24. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C: Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid; 2005 Jul;15(7):708-17
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of patients undergoing surgical treatment, 2761 (76.1%) patients were diagnosed with benign nodules, 858 (23.6%) with malignant nodules, and 10 (0.3%) with atypical adenoma (7 follicular and 3 Hürthle cells).

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053388.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122519.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047213
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / germ-cell AP isoenzyme; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


26. Salgado LR, Machado MC, Cukiert A, Liberman B, Kanamura CT, Alves VA: Cushing's disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol; 2006;17(2):191-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's disease arising from a clinically nonfunctioning pituitary adenoma.
  • A 49-yr-old woman with a large pituitary tumor leading to visual loss and galactorrhea- amenorrhea was submitted to transcranial pituitary surgery, when a clinically nonfunctioning pituitary adenoma was partially removed.
  • Histopathology and immunohistochemistry confirmed the diagnosis of "non-secreting atypical adenoma."
  • [MeSH-major] Adenoma / complications. Adenoma / pathology. Pituitary ACTH Hypersecretion / etiology. Pituitary Neoplasms / complications. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pituitary. 2000 Oct;3(2):117-22 [11141695.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 May;46(5):599-606 [9231056.001]
  • [Cites] Endocr Pathol. 1996 Spring;7(1):21-35 [12114677.001]
  • [Cites] J Neurosurg. 2004 Nov;101(5):874-7 [15540932.001]
  • [Cites] Aust N Z J Med. 1987 Apr;17(2):249-51 [3039955.001]
  • [Cites] Arch Intern Med. 1983 May;143(5):1040-2 [6089681.001]
  • [Cites] J Endocrinol Invest. 1997 Apr;20(4):240-4 [9211134.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Feb;22(2):147-53 [2985300.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Endocr J. 2002 Jun;49(3):285-92 [12201210.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1513-6 [7962351.001]
  • [Cites] Front Horm Res. 2004;32:205-16 [15281348.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):38-42 [16147581.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1619-23 [9589666.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Jun;18(2):339-58 [2663478.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Nov;41(5):661-6 [7828356.001]
  • [Cites] Pituitary. 2002;5(4):221-3 [14558669.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1089-94 [8496297.001]
  • [Cites] J Clin Endocrinol Metab. 1979 Jul;49(1):23-9 [221528.001]
  • [Cites] Endocr Pathol. 1996 Summer;7(2):145-150 [12114642.001]
  • (PMID = 17159252.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Osawa N, Onoda N, Kawajiri H, Tezuka K, Takashima T, Ishikawa T, Miyauchi A, Hirokawa M, Wakasa K, Hirakawa K: Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT. Int J Mol Med; 2009 Dec;24(6):733-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of parathyroid carcinoma from benign adenoma is often difficult when its typical clinicopathological features are absent, even with the aid of various molecular markers.
  • In contrast, one atypical adenoma stained positively and homogeneously, and the disease recurred three times clinically.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885612.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / nucleolin; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


28. Orfanos NF, Mariolis-Sapsakos T, Orfanos FN, Goutas N, Vlachodimitropoulos D, Antoniou AG: Giant parathyroid adenoma with atypical ultrasonographic image. Clin Nucl Med; 2007 Mar;32(3):239-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant parathyroid adenoma with atypical ultrasonographic image.
  • [MeSH-major] Adenoma / radionuclide imaging. Adenoma / ultrasonography. Parathyroid Neoplasms / radionuclide imaging. Parathyroid Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17314610.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down






Advertisement